Loading...
NPI 1922565506 · Skokie, IL · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Lifescan Labs Of Illinois, LLC is a clinical medical laboratory provider located in Skokie, Illinois. This profile covers 103 Medicare and 117 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Lifescan Labs Of Illinois, LLC |
| Address | 5255 Golf Rd |
| City | Skokie |
| State | IL |
| ZIP | 60077 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | March 1, 2019 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicaid | $58M |
| Medicare | $5.6M |
LIFESCAN LABS OF ILLINOIS, LLC’s business is overwhelmingly driven by high-volume SARS-CoV-2 testing: U0004 alone accounts for $2.6M of Medicare revenue (34.8K claims, 47.8% of this provider's Medicare revenue) and $38.6M of Medicaid revenue (593.6K claims, 67.6% of this provider's Medicaid revenue). Medicaid volumes for COVID PCR codes (U0004, U0005, G2023) are particularly large, indicating the lab operates at scale for state program testing demand.
Revenue is highly concentrated in a very small set of codes for both payers: the top three Medicare codes by revenue account for 67.1% of Medicare revenue, while the top three Medicaid codes account for 89.5% of Medicaid revenue. For Medicaid those top codes are visibly dominated by U0004, U0005 and G2023, showing dependency on a narrow service mix centered on COVID testing and related specimen collection.
The provider’s payer mix is heavily weighted toward Medicaid in absolute scale: Medicare lifetime revenue is $5.6M compared with Medicaid lifetime revenue of $58M. This imbalance means the organization’s financial performance and utilization profile are far more sensitive to Medicaid demand and reimbursement policies than to Medicare.
On competitive standing, LIFESCAN is an outlier on its highest-volume COVID codes: U0004 ranks #1 of 259 nationally in Medicare (100th percentile; extreme outlier) and #1 of 48 in-state for Medicaid (100th percentile; extreme outlier). G2023 is also well above peers (Medicare rank #8 of 465, 98th percentile; Medicaid rank #1 of 396, 100th percentile), indicating the provider is a major statewide testing supplier and a national leader on select Medicare COVID codes.
Operational patterns show a service model that includes both high-throughput laboratory testing and extensive specimen collection/field services. High counts for specimen-collection and travel allowances appear across payers — Medicare shows 49.1K claims for G0471 ($491.1K) and 439K claims for P9603 ($439K), while Medicaid shows 205.6K claims for P9604 ($411.1K) and 285.5K claims for G2023 ($5.7M) — consistent with outreach to SNFs, homebound patients, and mass-testing sites.
The provider was enumerated on 2019-03-01 (~7 years ago), placing its NPI activation shortly before the pandemic expansion in COVID testing. The timing is consistent with a rapid scale-up of high-throughput infectious disease testing lines captured in the code mix.
Several codes are flagged as statistical outliers or notably above typical volumes, reinforcing the unusual scale of certain services: Medicare shows extreme outlier status for U0004 (100th percentile) and 87635 (100th percentile), and Medicaid shows extreme outlier status for U0004 and U0005 (both 100th percentile). These labels indicate utilization that is far above typical peer volumes and should be interpreted as market-dominant activity rather than routine lab mix.
For payers and network analysts, the combination of extreme concentration in pandemic-era testing codes and very large Medicaid volumes (e.g., $38.6M for U0004 and total Medicaid $58M) suggests monitoring utilization trends and contract terms for SARS-CoV-2 testing, specimen-collection reimbursement, and travel allowances as demand normalizes. Given the reliance on a small set of codes (top-3 shares of 67.1% Medicare and 89.5% Medicaid), changes in public-health testing demand or coding rules would materially affect this provider’s revenue profile.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
103 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 34,830 | $70 | $2.6M |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 24,090 | $20 | $554.2K |
| G0471 | Collection of venous blood by venipuncture or urine sample by catheterization from an individual in a skilled nursing facility (snf) or by a laboratory on behalf of a home health agency (hha) | 49,110 | $10 | $491.1K |
| P9603 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled | 439,040 | $1 | $439K |
| 80053 | The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel. | 23,260 | $10 | $232.6K |
| 87635 | Using an amplified nucleic acid probe technique, the lab analyst performs the necessary steps to identify the nucleic acids from the severe acute respiratory syndrome coronavirus 2 (SARS–COV–2) virus… | 4,260 | $50 | $213.2K |
| 85025 | A complete blood count (better known as a CBC) is a blood test request by a doctor that provides detailed information about various types of cells in a patient's blood. Usually a pathologist or a… | 15,250 | $10 | $122K |
| 80048 | The lab analyst performs a basic metabolic pane (BMP) test in which he measures the blood level of eight chemicals including total calcium, sodium, potassium, chloride, carbon dioxide, glucose, blood… | 11,680 | $10 | $93.4K |
| 85027 | The lab analyst performs a blood count on the red and white blood cells and platelets also known as thrombocytes. He also determines the hemoglobin, typically by spectrophotometry, and the… | 14,790 | $10 | $88.7K |
| 84443 | The lab analyst performs a test to measure the amount of thyroid–stimulating hormone (TSH), a hormone produced in the pituitary gland that helps regulate thyroid function. The typical specimen is the… | 5,060 | $20 | $80.9K |
Showing 1–10 of 103
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 103 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
103 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| 87637 | 30 | 50 | 50 | $140 | $557.3K |
| U0004 | 1 | 20 | 530 | $70 | $383.5K |
| P9603 | 8 | 40 | 35,960 | $1 | $232.2K |
| G0471 | 2 | 10 | 940 | $10 | $166.2K |
| G2023 | 5 | 90 | 400 | $20 | $96.5K |
| 82140 | 5 | 10 | 100 | $10 | $71.4K |
| 87088 | 10 | 30 | 140 | $10 | $31.9K |
| 80307 | 66 | 70 | 120 | $60 | $27.2K |
| 87186 | 11 | 40 | 70 | $10 | $21.4K |
| P9604 | 3 | 30 | 310 | $10 | $18.7K |
Showing 1–10 of 103
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
117 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 593,610 | $70 | $38.6M |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 342,330 | $20 | $6.8M |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 285,480 | $20 | $5.7M |
| 80053 | The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel. | 101,910 | $10 | $917.2K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 10,110 | $80 | $798.7K |
| 85025 | A complete blood count (better known as a CBC) is a blood test request by a doctor that provides detailed information about various types of cells in a patient's blood. Usually a pathologist or a… | 145,500 | $10 | $727.5K |
| G2024 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen… | 21,870 | $20 | $525K |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | 205,570 | $1 | $411.1K |
| 84443 | The lab analyst performs a test to measure the amount of thyroid–stimulating hormone (TSH), a hormone produced in the pituitary gland that helps regulate thyroid function. The typical specimen is the… | 28,780 | $10 | $402.9K |
| 80048 | The lab analyst performs a basic metabolic pane (BMP) test in which he measures the blood level of eight chemicals including total calcium, sodium, potassium, chloride, carbon dioxide, glucose, blood… | 50,450 | $10 | $353.1K |
Showing 1–10 of 117
How this provider's Medicaid billing volume and revenue compare to other Illinois providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Illinois median
117 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 1 | 50 | 710 | $70 | $1.2M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 36 | 350 | 400 | $70 | $514.7K |
| 87637 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, influenza B, and respiratory syncytial virus (RSV)… | 55 | 80 | 530 | $130 | $505.1K |
| G2024 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen… | 5 | 20 | 470 | $20 | $351.2K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 112 | 280 | 1,120 | $30 | $218.9K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 1 | 210 | 680 | $20 | $206.4K |
| 87389 | The lab analyst performs a test to screen for human immunodeficiency virus, called HIV. The test screens for antigens of the HIV 1 virus and antibodies to the HIV 1 and HIV 2 viruses using an… | 126 | 250 | 450 | $40 | $185.7K |
| 87591 | The lab analyst performs a lab test for Neisseria gonorrhoeae, also called GC, using amplified nucleic acid probe technique. | 275 | 360 | 600 | $30 | $165.1K |
| 87491 | The lab analyst performs a test for Chlamydia trachomatis using amplified nucleic acid probe technique. | 277 | 360 | 630 | $30 | $165K |
| 87661 | The lab analyst performs a test for Trichomonas vaginalis using nucleic acid amplified probe technique. | 122 | 160 | 300 | $20 | $145.2K |
Showing 1–10 of 117
Other providers in the same ZIP code as Lifescan Labs Of Illinois, LLC, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.